Masafumi Ikeda

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Thomas Yau, Peter R. Galle, Thomas Decaens et al. · The Lancet · 2025 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Four Cases of Pancreatic Acinar Cell Carcinoma Treated with Gemcitabine or S-1 as a Single Agent

Yasuo Seki, Takushi Okusaka, Masafumi Ikeda et al. · Japanese Journal of Clinical Oncology · 2009 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Predictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma

Masafumi Ikeda, Takushi Okusaka, Hideki Ueno et al. · Japanese Journal of Clinical Oncology · 2008 · 16 citations · Full text

Medicine, Oncology, Pharmacology +16

Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

Masatoshi Kudo, Tatsuya Yamashita, Richard S. Finn et al. · Liver Cancer · 2025 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma

Yoshihisa Kodama, Kazuomi Ueshima, Michihisa Moriguchi et al. · BMC Cancer · 2025 · 10 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17